Clinical TrialsSearch results
Number of results: 2579
Recruiting
- A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations.
- Chronic Obstructive Pulmonary Disease (COPD)
- Ageishi Yuji
- 2023-02-23
Other
- A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to
Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations
- COPD
- Ageishi Yuji
- 2022-01-19
Recruiting
- A Phase III, Randomised, Double-Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
- Chronic Kidney Disease and Hypertension
- Ageishi Yuji
- 2024-04-23
Recruiting
- A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib.
- Carcinoma, Non-Small-Cell Lung
- Hibi Kazushige
- 2022-10-27
Completed
- A phase III, randomized, active-comparator, non-inferiority study to demonstrate the Immunogenicity and Safety of DS-5670a in children 12 through 17 years of age.
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2022-10-20
Not yet recruiting
- A phase III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670d (monovalent: omicron XBB.1.5) in children 5 through 11 years of age
- Prevention of infection due to SARS-CoV-2
- Inoguchi Akihiro
- 2023-10-24
Other
- A phase III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670d(monovalent: omicron XBB.1.5) in adults and children aged 12 years and older
- Prevention of infection due to SARS-CoV-2
- Inoguchi Akihiro
- 2023-10-24
Recruiting
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for the Treatment of Common Warts (Verruca vulgaris) in Adolescents and Adults (CFW-3A)
- Common Warts (Verruca vulgaris)
- Kanmuri Kazuhiro
- 2023-09-12
Recruiting
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- Chronic Obstructive Pulmonary Disease (COPD)
- Tsurumaki Sachi
- 2024-02-07